Russian Medical Inquiry
ISSN 2587-6821 (Print), 2686-9918 (Online)

The experience of passive immunization against respiratory syncytial viral infection: the twelfth season

Open accessCrossrefAntiplagiat



Impact factor - 0,591*

* Impact factor according to the SCIENCE INDEX 2021

DOI: 10.32364/2587-6821-2022-6-11-659-666

A.K. Mironova1,2

1Z.A. Bashlyaeva Children’s City Clinical Hospital, Moscow, Russian Federation

2Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation

Respiratory syncytial virus (RSV) is the most common pathogenic agent responsible for respiratory viral infections in infants and young children. Therefore, the importance of research in the field has been driven by the need for effective preventive tools against RSV infection for children, especially those at high risk of severe RSV disease. Despite the on-going efforts to develop RSV vaccines, the passive immunization of children with a drug called palivizumab is the only reliable option for prophylactic use against RSV. The article presents data on the passive immunization carried out in Moscow in the 2021–2022 season, including the following: the patient routing, indications for immunization, and the organization of the immunization process. It also provides authors’ own data on the number of immunized preterm children born with low and extremely low birth weight which were collected during 11 immunization seasons. The article also reviews the structure of morbidity in this group of children. The authors emphasize a high prevalence of the comorbidity of respiratory and cardiovascular diseases.

Keywords: respiratory syncytial virus, preterm infants, very low body weight, very low birth weight (VLBW), extremely low birth weight (ELBW), bronchopulmonary dysplasia, immunoprophylaxis, palivizumab.

For citation: Mironova A.K. The experience of passive immunization against respiratory syncytial viral infection: the twelfth season. Russian Medical Inquiry. 2022;6(11):659–666 (in Russ.). DOI: 10.32364/2587-6821-2022-6-11-659-666.

About the author:

Alena K. Mironova — C. Sc. (Med.), Head of the Rehabilitation therapy center for children younger than 3 years old, Z.A. Bashlyaeva Children’s City Clinical Hospital; 28, Geroev Panfilovtsev str., Moscow, 125373, Russian Federation; assistant of the Academician G.N. Speransky Department of Pediatrics, Russian Medical Academy of Continuous Professional Education; 2/1, Barrikadnaya str., Moscow, 125993, Russian Federation; ORCID iD 0000-0002-7864-5090.

Contact information: Alena K. Mironova, e-mail:

Financial Disclosure: the author has no a financial or property interest in any material or method mentioned.

There is no conflict of interests.

Received 12.09.2022.

Revised 05.10.2022.

Accepted 28.10.2022.

1. Robinson K.A., Odelola O.A., Saldanha I., McKoy N. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev. 2010;(2):CD007743. DOI: 10.1002/14651858.CD007743.pub2. Update in: Cochrane Database Syst Rev. 2012;2:CD007743.
2. Bedoya V.I., Abad V., Trujillo H. Frequency of respiratory syncytial virus in hospitalized infants with lower acute respiratory tract infection in Colombia. Pediatr Infect Dis J. 1996;15(12):1123–1124. DOI: 10.1097/00006454-199612000-00014.
3. Hussey G.D., Apolles P., Arendse Z. et al. Respiratory syncytial virus infection in children hospitalised with acute lower respiratory tract infection. S Afr Med J. 2000;90(5):509–512. PMID: 10901825.
4. Moyes J., Cohen C., Pretorius M.; South African Severe Acute Respiratory Illness Surveillance Group. Epidemiology of respiratory syncytial virus-associated acute lower respiratory tract infection hospitalizations among HIV-infected and HIV-uninfected South African children, 2010–2011. J Infect Dis. 2013;208(Suppl 3):S217–S226. DOI: 10.1093/infdis/jit479.
5. Moyes J., Walaza S., Pretorius M. et al.; South African Severe Acute Respiratory Illness (SARI) Surveillance Group. Respiratory syncytial virus in adults with severe acute respiratory illness in a high HIV prevalence setting. J Infect. 2017;75(4):346–355. DOI: 10.1016/j.jinf.2017.06.007.
6. Ovsyannikov D.Yu., Tsverava A.G., Krsheminskaya I.V. et al. Patients with bronchopulmonary dysplasia are at risk of severe bronchiolitis caused by respiratory syncytial virus. Neonatology: News, Opinions, Training. 2022;10(4):63–74 (in Russ.). DOI: 10.33029/2308-2402-2022-10-4-63-74.
7. Suleiman-Martos N., Caballero-Vázquez A., Gómez-Urquiza J.L. et al. Prevalence and Risk actors of Respiratory Syncytial Virus in Children under 5 Years of Age in the WHO European Region: A Systematic Review and Meta-Analysis. J Pers Med. 2021;11:416. DOI: 10.3390/jpm11050416.
8. Ovsyannikov D.Yu., Krsheminskaya I.V., Ukraintsev S.E. Acute bronchiolitis. Neonatal pulmonology. Ovsyannikov D.Yu., ed. M.; 2022 (in Russ.).
9. Ovsyannikov D.Yu., Krsheminskaya I.V. Acute bronchiolitis. Pediatric pulmonology: a national guide. Blokhin B.M., ed. M.: GEOTAR-Media; 2021:358–373 (in Russ.). DOI: 10.33029/9704-5857-0-2021-DEP-1-960.
10. Bokeria E.L., Degtyareva E.A., Kovalev I.A., Soldatova I.G. Respiratory syncytial viral infection in children with congenital heart defects: the relevance of the problem and recommendations for prevention. Russian Bulletin of Perinatology and Pediatrics. 2014;59(5):101–108 (in Russ.).
11. Tatochenko V.K., Bakradze M.D. Pediatrician for every day — 2022. Fevers: Handbook of diagnosis and treatment. M.: FSAU "NMIC of Children’s Health" of the Ministry of Health of Russia; 2022:91–99 (in Russ.).
12. Malakhov A.B., Angel A.E., Berezhanskiy P.V. et al. Interleukin profile in children with acute bronchiolitis (raw data). Doctor.Ru. 2021;20(10):12–17 (in Russ.). DOI: 10.31550/1727-2378- 2021-20-10-12-17].
13. Rocca A., Biagi C., Scarpini S. et al. Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now? Int J Mol Sci. 2021;22(7):3703. DOI: 10.3390/ijms22073703.
14. Clinical guidelines. Acute bronchiolitis. M.; 2021 (in Russ.).
15. Mascola J.R., Fauci A.S. Novel vaccine technologies for the 21st century. Nat Rev Immunol. 2020;20(2):87–88. DOI: 10.1038/s41577-019-0243-3.
16. Walsh E.E., Falsey A.R., Scott D.A. et al. A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine. J Infect Dis. 2022;225(8):1357–1366. DOI: 10.1093/infdis/jiab612.
17. Schmoele-Thoma B., Zareba A.M., Jiang Q. et al. Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study. N Engl J Med. 2022;386(25):2377–2386. DOI: 10.1056/NEJMoa2116154.
18. Garegnani L., Styrmisdóttir L., Roson Rodriguez P. et al. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev. 2021;11(11):CD013757. DOI: 10.1002/14651858.CD013757.pub2.
19. Zimmer G., Budz L., Herrler G. Proteolytic activation of respiratory syncytial virus fusion protein. Cleavage at two furin consensus sequences. J Biol Chem. 2001;276(34):31642–3150. DOI: 10.1074/jbc.M102633200.
20. Lamb R.A., Parks G.D. Paramyxoviridae: the viruses and their replication. In: Knipe D.M., Howley P.M., eds. Fields Virology. 5.1. Wolters Kluver: Lippencott Williams and Wilkins. 2007:1449–1496.
21. Dessain S.K. Human antibody therapeutics for viral disease. Berlin: Springer Verlag. 2021.
22. Reeves R.M., van Wijhe M., Lehtonen T. et al.; RESCEU Investigators. A Systematic Review of European Clinical Practice Guidelines for Respiratory Syncytial Virus Prophylaxis. J Infect Dis. 2022;226(Suppl 1):S110–S116. DOI: 10.1093/infdis/jiac059.
23. Ginsberg G.M., Somekh E., Schlesinger Y. Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? — a cost-utility analysis. Isr J Health Policy Res. 2018;7(1):63. DOI: 10.1186/s13584-018-0258-4.
24. Wang D., Bayliss S., Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess. 2011;15(5):iii–iv, 1–124. DOI: 10.3310/hta15050.
25. Lewis L., Sinha I., Losty P.D. Respiratory syncytial virus bronchiolitis in congenital diaphragmatic hernia: A systematic review of prevalence rates and palivizumab prophylaxis. Pediatr Pulmonol. 2022;57:239–244. DOI: 10.1002/ppul.25717.
26. Mironova A.K., Osmanov I.M., Sharykin A.S. Experience of passive immunoprophylaxis against respiratory syncytial viral infection in children born with very low and extremely low body weight. Russian Bulletin of Perinatology and Pediatrics. 2020;65:(4):134–141 (in Russ.). DOI: 10.21508/1027-4065-2020-65-4-134-141.
27. Galvis C., Colmenares A., Cabrales L. et al. Impact of immunoprophylaxis with palivizumab on respiratory syncytial virus infection in preterm infants less than 35 weeks in Colombian hospitals. Pediatr Pulmonol. 2022;57(10):2420–2427. DOI: 10.1002/ppul.26051.
28. Narayan O., Bentley A., Mowbray K. et al. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK. J Med Econ. 2020;23(12):1640–1652. DOI: 10.1080/13696998.2020.1836923.
29. Sanders S.L., Agwan S., Hassan M. et al. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection. Cochrane Database Syst Rev. 2019;8(8):CD009417. DOI: 10.1002/14651858.CD009417.pub2.
30. Yeo K.T., Yung C.F., Khoo P.C. et al. Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation. J Infect Dis. 2021;224(2):279–287. DOI: 10.1093/infdis/jiaa749.
31. Instructions for the medical use of the drug Synagis®. (Electronic resource.) URL: (access date: 09.03.2022) (in Russ.).
32. Clinical guidelines. Immunoprophylaxis of infectious diseases in premature infants. Baranov A.A., Namazova-Baranova L.S., Belyaeva I.A. et al., eds. Moscow: Pediatr; 2019 (in Russ.).
33. Mironova A.K., Osmanov I.M. Experience of passive immunization against RSV infection in preterm infants. Pediatrician’s Practice. 2021;(4):31–36 (in Russ.).

License Creative Commons
This work is licensed under a Creative Commons «Attribution» 4.0 License.

Previous article
Next article